Axillary Metastasis
Mostrando 1-12 de 21 artigos, teses e dissertações.
-
1. An easy and practical prognostic parameter: tumor–stroma ratio in Luminal, Her2, and triple-negative breast cancers
SUMMARY OBJECTIVE: The stroma surrounding the tumor cells is important in tumor progression and treatment resistance, besides the properties of tumor cells. Studies on the tumor stroma characteristics will contribute to the knowledge for new treatment approaches. METHODS: A total of 363 breast cancer patients were evaluated for the tumor–stroma ratio. Th
Revista da Associação Médica Brasileira. Publicado em: 2022
-
2. Poorly differentiated synovial sarcoma in the wrist - Case report
Synovial sarcomas are rare malignant tumors affecting mainly young adults, presenting as a slow growth mass located in deep soft tissues of extremities, near the joints. In this report a 34-year-old male patient, presented an ulcerovegetative lesion on the right wrist which was completely excised. Histopathology and immunohistochemistry confirmed synovial sa
An. Bras. Dermatol.. Publicado em: 2014-09
-
3. Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
OBJECTIVE: To analyze the expression of hypoxia-inducible factors (hypoxia-inducible factor 1A and hypoxia-inducible factor 2A) and aldehyde dehydrogenase proteins in patients with locally advanced breast carcinoma who were subjected to neoadjuvant chemotherapy. METHODS: We included 90 patients with histologically confirmed stage II and III breast carcino
Clinics. Publicado em: 2013-05
-
4. Sentinel node biopsy in breast cancer: results in a large series
Sentinel lymph node biopsy (SLNB) is an appropriate method for the evaluation of axillary status in cases of early breast cancer. We report our experience in treating cases evaluated using SLNB. We analyzed a total of 1192 cases assessed by means of SLNB from July 1999 to December 2007. SLNB processing was successfully completed in 1154 cases with the use of
Brazilian Journal of Medical and Biological Research. Publicado em: 2010-06
-
5. Transição epitélio-mesenquimal e presença de células CD44+/CD24- como fatores de predição de metástase axilar no câncer de mama inicial / Epithelial-mesenchymal transition and the CD44+/CD24- cells as predicting factors for lymph node metastasis in early breast cancer
Sabemos hoje que os tumores sólidos apresentam uma composição celular heterogênia e que apenas uma pequena parcela dessas células apresenta capacidade de se proliferar e gerar novos tumores. Estudos prévios sobre a formação do câncer de mama têm sido realizados com base na combinação dos marcadores de superfície celular CD44 e CD24. Já foi demo
Publicado em: 2010
-
6. Produção de VEGF e HIF-1? em pacientes com carcinoma de mama localmente avançado submetidas à quimioterapia neoadjuvante. / Production of VEGF and HIF-1? in patients with locally advanced breast cancer primarily submitted to neoadjuvant chemotherapy.
To determine the predictive and prognostic value of vascular endothelial growth factor (VEGF) and Hypoxia-inducible factor-1 (HIF-1?) for relapse-free survival (RFS) and overall survival (OS) in locally advanced breast cancer (LABC) primarily submitted to neoadjuvant chemotherapy. MATERIALS AND METHODS: VEGF and HIF were quantitatively measured in plasma sam
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 09/05/2008
-
7. Localização histologica das metastases nos linfonodos sentinelas e fatores de risco para predizer positividade dos linfonodos não-sentinelas em cancer de mama / Histologic localization of sentinel lymph nodes metastases and risk factors for prediction of non-sentinel lymph nodes positivity in breast cancer
INTRODUCTION: The complete axillary lymph node dissection is the standard treatment for patients with positive sentinel lymph node (SLN) in breast cancer. However, several studies report that 38 to 67% of patients with positive SLN do not have involvement of the non-sentinel lymph nodes (NSLN). OBJECTIVE: The purpose of this study is to explore the orphologi
Publicado em: 2007
-
8. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection?
OBJECTIVE: To determine the likelihood of nonsentinel axillary metastasis in the presence of sentinel node metastasis from a primary breast carcinoma. SUMMARY BACKGROUND DATA: Sentinel lymphadenectomy is a highly accurate technique for identifying axillary metastasis from a primary breast carcinoma. Our group has shown that nonsentinel axillary lymph nodes a
-
9. Improved axillary staging of breast cancer with sentinel lymphadenectomy.
OBJECTIVE: The authors evaluated the effect of intraoperative lymphatic mapping and sentinel lymphadenectomy (SLND) on the axillary staging of patients with carcinoma of the breast. SUMMARY BACKGROUND DATA: The accurate staging of patients with breast cancer is essential to guide management and determine prognosis. The authors previously reported the feasibi
-
10. Benign lymph node inclusions mimicking metastatic carcinoma.
AIMS--To draw attention to non-neoplastic inclusions in axillary lymph nodes removed from women with primary breast cancer which may be mistaken for metastases. METHODS--Five examples of non-malignant inclusions were detected in axillary lymph nodes removed from women with mammary carcinoma. Immunohistochemical staining for CAM 5.2 and S100 markers, as well
-
11. Immunohistochemical characteristics of human milk-fat globule antibodies in predicting chest wall and distant metastasis after mastectomy for localized cancer of the breast.
Because postoperative radiation reduces chest wall metastasis after mastectomy, it is important to identify patients in whom it might develop. Pathologic and immunohistochemical features in 59 patients with chest wall metastasis were compared with characteristics in disease-free patients and patients with systemic metastases without chest wall metastasis. Im
-
12. Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
The present clinical trial update consists of a review of two of eight current studies (the 10981-22023 AMAROS trial and the 10994 p53 trial) of the European Organization for Research and Treatment of Cancer Breast Cancer Group, as well as a preview of the MIND-ACT trial. The AMAROS trial is designed to prove equivalent local/regional control for patients wi
BioMed Central.